Change in serum dehydroepiandrosterone, testosterone, insulin-like growth factor-1, and osteocalcin levels with the third generation selective estrogen receptor modulator arzoxifene (LY353381·HCI)

C. J. Fabian, J. Anderson, C. Chamberlain, B. F. Kimler, M. S. Mayo, J. A. O'Shaughnessy, Henry T. Lynch, K. A. Johnson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Phase I trials of arzoxifene, a third generation SERM lacking uterine agoninst actvity, have reported reductions in serum IGF-1 or IGF-1/IGFBP-3 ratio. Little information is available on serum levels of DHEA and free testosterone, known risk factors for postmenopausal breast cancer. As part of an ongoing Phase II chemoprevention trial of arzoxifene in high risk women, serum for a variety of biomarkers was obtained and frozen at baseline, after six months of arzoxifene 20 mg/day vs placebo, and again following six months of open label arzoxifene. A vanguard group of 24 subjects has completed study and results at baseline and study completion are available for the initial 14 subjects. Both pre- and post-menopausal subjects were eligible, with hormone replacement allowed providing women had been on continuously for ≥6 months prior to entry. No changes in hormonal treatment were allowed during the study. Serum was obtained (during the follicular portion of the cycle, D1-14, for premenopausal women) and stored frozen until analysis. Median age was 49.5 years (range 43-61) and median baseline estradiol level was 68 pg/ml (

Original languageEnglish
Pages (from-to)225
Number of pages1
JournalBreast Cancer Research and Treatment
Volume69
Issue number3
StatePublished - 2001

Fingerprint

LY 353381
Selective Estrogen Receptor Modulators
Dehydroepiandrosterone
Osteocalcin
Somatomedins
Testosterone
Serum
Insulin-Like Growth Factor I
Insulin-Like Growth Factor Binding Protein 3
Chemoprevention
Estradiol
Biomarkers
Placebos
Hormones
Breast Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Change in serum dehydroepiandrosterone, testosterone, insulin-like growth factor-1, and osteocalcin levels with the third generation selective estrogen receptor modulator arzoxifene (LY353381·HCI). / Fabian, C. J.; Anderson, J.; Chamberlain, C.; Kimler, B. F.; Mayo, M. S.; O'Shaughnessy, J. A.; Lynch, Henry T.; Johnson, K. A.

In: Breast Cancer Research and Treatment, Vol. 69, No. 3, 2001, p. 225.

Research output: Contribution to journalArticle

@article{9708317f3607409da024649a163aa95a,
title = "Change in serum dehydroepiandrosterone, testosterone, insulin-like growth factor-1, and osteocalcin levels with the third generation selective estrogen receptor modulator arzoxifene (LY353381·HCI)",
abstract = "Phase I trials of arzoxifene, a third generation SERM lacking uterine agoninst actvity, have reported reductions in serum IGF-1 or IGF-1/IGFBP-3 ratio. Little information is available on serum levels of DHEA and free testosterone, known risk factors for postmenopausal breast cancer. As part of an ongoing Phase II chemoprevention trial of arzoxifene in high risk women, serum for a variety of biomarkers was obtained and frozen at baseline, after six months of arzoxifene 20 mg/day vs placebo, and again following six months of open label arzoxifene. A vanguard group of 24 subjects has completed study and results at baseline and study completion are available for the initial 14 subjects. Both pre- and post-menopausal subjects were eligible, with hormone replacement allowed providing women had been on continuously for ≥6 months prior to entry. No changes in hormonal treatment were allowed during the study. Serum was obtained (during the follicular portion of the cycle, D1-14, for premenopausal women) and stored frozen until analysis. Median age was 49.5 years (range 43-61) and median baseline estradiol level was 68 pg/ml (",
author = "Fabian, {C. J.} and J. Anderson and C. Chamberlain and Kimler, {B. F.} and Mayo, {M. S.} and O'Shaughnessy, {J. A.} and Lynch, {Henry T.} and Johnson, {K. A.}",
year = "2001",
language = "English",
volume = "69",
pages = "225",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Change in serum dehydroepiandrosterone, testosterone, insulin-like growth factor-1, and osteocalcin levels with the third generation selective estrogen receptor modulator arzoxifene (LY353381·HCI)

AU - Fabian, C. J.

AU - Anderson, J.

AU - Chamberlain, C.

AU - Kimler, B. F.

AU - Mayo, M. S.

AU - O'Shaughnessy, J. A.

AU - Lynch, Henry T.

AU - Johnson, K. A.

PY - 2001

Y1 - 2001

N2 - Phase I trials of arzoxifene, a third generation SERM lacking uterine agoninst actvity, have reported reductions in serum IGF-1 or IGF-1/IGFBP-3 ratio. Little information is available on serum levels of DHEA and free testosterone, known risk factors for postmenopausal breast cancer. As part of an ongoing Phase II chemoprevention trial of arzoxifene in high risk women, serum for a variety of biomarkers was obtained and frozen at baseline, after six months of arzoxifene 20 mg/day vs placebo, and again following six months of open label arzoxifene. A vanguard group of 24 subjects has completed study and results at baseline and study completion are available for the initial 14 subjects. Both pre- and post-menopausal subjects were eligible, with hormone replacement allowed providing women had been on continuously for ≥6 months prior to entry. No changes in hormonal treatment were allowed during the study. Serum was obtained (during the follicular portion of the cycle, D1-14, for premenopausal women) and stored frozen until analysis. Median age was 49.5 years (range 43-61) and median baseline estradiol level was 68 pg/ml (

AB - Phase I trials of arzoxifene, a third generation SERM lacking uterine agoninst actvity, have reported reductions in serum IGF-1 or IGF-1/IGFBP-3 ratio. Little information is available on serum levels of DHEA and free testosterone, known risk factors for postmenopausal breast cancer. As part of an ongoing Phase II chemoprevention trial of arzoxifene in high risk women, serum for a variety of biomarkers was obtained and frozen at baseline, after six months of arzoxifene 20 mg/day vs placebo, and again following six months of open label arzoxifene. A vanguard group of 24 subjects has completed study and results at baseline and study completion are available for the initial 14 subjects. Both pre- and post-menopausal subjects were eligible, with hormone replacement allowed providing women had been on continuously for ≥6 months prior to entry. No changes in hormonal treatment were allowed during the study. Serum was obtained (during the follicular portion of the cycle, D1-14, for premenopausal women) and stored frozen until analysis. Median age was 49.5 years (range 43-61) and median baseline estradiol level was 68 pg/ml (

UR - http://www.scopus.com/inward/record.url?scp=0037975297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037975297&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 225

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -